Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety,
tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine
and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or
metastatic pancreatic adenocarcinoma.